These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29316075)

  • 1. Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients.
    Yang B; Wang C; Xie Y; Xu L; Wu X; Wu D
    Cancer Sci; 2018 Mar; 109(3):777-784. PubMed ID: 29316075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Metabolomics of Chronic Myelogenous Leukemia Based on GC-MS].
    Yang BY; Li XL; Yao Y; Wang C; Chen SN; Wu XJ; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1585-1591. PubMed ID: 29262880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients.
    Karlíková R; Široká J; Friedecký D; Faber E; Hrdá M; Mičová K; Fikarová I; Gardlo A; Janečková H; Vrobel I; Adam T
    J Proteome Res; 2016 Sep; 15(9):3158-66. PubMed ID: 27465658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.
    de Almeida FC; Berzoti-Coelho MG; Toro DM; Cacemiro MDC; Bassan VL; Barretto GD; Garibaldi PMM; Palma LC; de Figueiredo-Pontes LL; Sorgi CA; Faciolli LH; Gardinassi LG; de Castro FA
    Front Immunol; 2022; 13():840173. PubMed ID: 35493444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAM8 Is an Antigen of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia Cells Identified by Patient-Derived Induced Pluripotent Stem Cells.
    Miyauchi M; Koya J; Arai S; Yamazaki S; Honda A; Kataoka K; Yoshimi A; Taoka K; Kumano K; Kurokawa M
    Stem Cell Reports; 2018 Mar; 10(3):1115-1130. PubMed ID: 29429960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
    Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
    Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovering gene expression signatures responding to tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
    Cha K; Li Y; Yi GS
    BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):29. PubMed ID: 27534394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
    Zhu Y; Lu L; Qiao C; Shan Y; Li H; Qian S; Hong M; Zhao H; Li J; Yang Z; Chen Y
    Oncogene; 2018 May; 37(21):2837-2849. PubMed ID: 29511345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.
    Meenakshi Sundaram DN; Jiang X; Brandwein JM; Valencia-Serna J; Remant KC; Uludağ H
    Drug Discov Today; 2019 Jul; 24(7):1355-1369. PubMed ID: 31102734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
    Kelani R; Monem F
    Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
    El Eit R; Itani AR; Nassar F; Rasbieh N; Jabbour M; Santina A; Zaatari G; Mahon FX; Bazarbachi A; Nasr R
    Cancer; 2019 Aug; 125(16):2818-2828. PubMed ID: 31034603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
    Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
    Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
    Wang J; Hu J; Jin Z; Wan H
    Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
    Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
    Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.